PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas (Q38007118)

26 August 2017

title

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas (English)

1 reference

26 August 2017

Hadara Rubinfeld

1

1 reference

26 August 2017

Ilan Shimon

series ordinal

2

1 reference

26 August 2017

publication date

3 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

42

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

285-291

1 reference

Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Medical therapy for clinically non-functioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Treatment of pituitary tumors: somatostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Wnt pathway inhibitors are strongly down-regulated in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Lineage-Specific Restraint of Pituitary Gonadotroph Cell Adenoma Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Pituitary tumours: all silent on the epigenetics front

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Predicting recurrence of nonfunctioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

ZAC1 target genes and pituitary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

PTEN: a new guardian of the genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Identification of a tumour suppressor network opposing nuclear Akt function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Epidermal growth factor binding sites in human pituitary macroadenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Expression and function of ErbB receptors and ligands in the pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Eps8 in the midst of GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Diagnosis and management of nonfunctioning pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Octreotide treatment does not affect the size of most non-functioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Recent clinical and pathophysiological advances in non-functioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Levels of p27 sensitize to dual PI3K/mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Cross-talk and modulation of signaling between somatostatin and growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Signaling pathway networks mined from human pituitary adenoma proteomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-012-9682-3

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

21 January 2018

1 reference

12 December 2020

Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors

1 reference

12 December 2020

Enhanced protein kinase B/Akt signalling in pituitary tumours

1 reference

12 December 2020

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

1 reference

12 December 2020

Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas

1 reference

12 December 2020

Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro.

1 reference

12 December 2020

Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro

1 reference

12 December 2020

Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals

1 reference

12 December 2020

A mutation and expression analysis of the oncogene BRAF in pituitary adenomas

1 reference

12 December 2020

High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy

1 reference

12 December 2020

The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas.

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

IGF1 induces cell proliferation in human pituitary tumors - functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors

1 reference

12 December 2020

Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland

1 reference

12 December 2020

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness

1 reference

12 December 2020

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

1 reference

12 December 2020

Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro

1 reference

12 December 2020

Cyclin D and cyclin E expression in normal and adenomatous pituitary

1 reference

12 December 2020

10.1007/S12020-012-9682-3

Identifiers

DOI

1 reference

26 August 2017

1 reference